Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 16;11(9):153.
doi: 10.1038/s41408-021-00549-6.

BCL-W expression associates with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified

Mario L Marques-Piubelli #  1 , Luisa M Solis #  1 , Edwin R Parra  1 , Luis Malpica Castillo  2 , Sushanth Gouni  2 , Ranjit Nair  2 , Dai Chihara  2 , Marina Konopleva  3 , Ignacio I Wistuba  1 , Swaminathan P Iyer  2 , Francisco Vega #  4 , Paolo Strati #  5   6
Affiliations

BCL-W expression associates with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified

Mario L Marques-Piubelli et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

PS is a consultant for Genentech-Roche and has received research support from AstraZeneca. FV received research funding/support from National Cancer Institute, CRISP Therapeutics, Geron Therapeutics, and honoraria from 13Health, Elsevier, America Registry of Pathology, Congressionally Directed Medical Research Program, and Society of Hematology Oncology. The remaining authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Association between BCL-2 family proteins expression and baseline characteristics, and survival according to BCL-W expression.
A Association between BCL-2A1 levels and previous therapy, and BCL-2 lvels and Th2 phenotype. B BCL-2 immunostain shows strong positivity in only 10% of lymphoma cells (low expression). C BCL-2 immunostain shows strong expression in 100% of lymphoma cells (high expression). D BCL-2A1 immunostain shows negativity in all lymphoma cells (low expression). E BCL-2A1 immunostain shows diffuse and moderate to strong cytoplasmic expression in 80% of lymphoma cells (high expression). F Progression-free survival according to BCL-W expression. G Overall survival according to BCL-W expression. H BCL-W immunostain shows weak cytoplasmic positivity in 40% of lymphoma cells (low expression). I BCL-W immunostain shows diffuse and intense expression in 100% of lymphoma cells (high expression).
See this image and copyright information in PMC

References

    1. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9:47–59. doi: 10.1038/nrm2308. - DOI - PubMed
    1. Del Gaizo Moore V, Letai A. BH3 profiling-measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett. 2013;332:202–5. doi: 10.1016/j.canlet.2011.12.021. - DOI - PMC - PubMed
    1. Pollyea DA, Amaya M, Strati P, Konopleva MY. Venetoclax for AML: changing the treatment paradigm. Blood Adv. 2019;3:4326–35. doi: 10.1182/bloodadvances.2019000937. - DOI - PMC - PubMed
    1. Marques-Piubelli ML, Schlette EJ, Khoury JD, Furqan F, Vega F, Soto LMS, et al. Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax. Leukemia Lymphoma. 2020;62:1129–35. doi: 10.1080/10428194.2020.1861278. - DOI - PubMed
    1. Rassidakis GZ, Jones D, Lai R, Ramalingam P, Sarris AH, McDonnell TJ, et al. BCL-2 family proteins in peripheral T-cell lymphomas: correlation with tumour apoptosis and proliferation. J Pathol. 2003;200:240–8. doi: 10.1002/path.1346. - DOI - PubMed

Publication types

Substances